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ABSTRACT
A series of benzo[b]thiophen-3-ols were synthesised and investigated as potential human monoamine oxi-
dase (hMAO) inhibitors in vitro as well as ex vivo in rat cortex synaptosomes by means of evaluation of
3,4-dihydroxyphenylacetic acid/dopamine (DOPAC/DA) ratio and lactate dehydrogenase (LDH) activity.
Most of these compounds possessed high selectivity for the MAO-B isoform and a discrete antioxidant
and chelating potential. Molecular docking studies of all the compounds underscored potential binding
site interactions suitable for MAO inhibition activity, and suggested structural requirements to further
improve the activity of this scaffold by chemical modification of the aryl substituents. Starting from this
heterocyclic nucleus, novel lead compounds for the treatment of neurodegenerative disease could
be developed.
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1. Introduction
Monoamine oxidases (MAOs; EC 1.4.3.4) are mitochondrial bound
flavoenzymes, which catalyse the oxidative degradation of amines.
The two human isoforms (hMAO-A and B) are quite similar sharing
70% sequence identity1,2 and are co-expressed, to almost the
same extent, in the majority of human tissues. However, some dif-
ferences in the distribution exist with hMAO-A being the isoform
predominantly expressed in placenta and intestinal tract, while
hMAO-B is more abundant in the brain and liver. In the central
nervous system (CNS), they modulate monoamine levels and thus
participate in the complex system that controls the physiological
and functional concentrations of these neurotransmitters. The two
MAO enzymes share similar affinity for dopamine, epinephrine,
norepinephrine, and tyramine; serotonin is the preferred substrate
for hMAO-A, while hMAO-B has high affinity for benzylamine3.
The products deriving from hMAO enzymatic activity are alde-
hydes and the ammonium ion, while the by-product hydrogen
peroxide (H2O2) is formed in order to regenerate the catalytically
active form of the FAD cofactor4. Although aldehydes do not
appear to accumulate in the healthy brain, some studies have
shown that elevated concentration of these products may exert
cytotoxic effects5. Moreover, the abnormal expression or increased
activity of hMAOs may lead to the excessive production of H2O2
that can expose cells to oxidative damage. In this respect, H2O2
participates in the Fenton reaction6 and reacts with certain cations
such as Cuþ and/or Fe2þ which leads to reactive the formation of
oxygen species (ROS). ROS are less stable than H2O2 and immedi-
ately react with the surrounding protein systems, which leads to
structural/functional damages and cells death7. MAO-mediated
oxidative stress has been associated with different neurodegenera-
tive pathologies as well as cardiomyopathies. This suggests that
reducing the activity of the hMAOs could be useful in order to
protect cells8–10.
An extensive number of natural and synthetic compounds
have shown effective inhibition of the hMAOs4,11,12. Keeping in
mind the structure and properties of endogenous substrates and
reversible inhibitors that bind to hMAOs, Wouters et al.13 pro-
posed that ideal MAO inhibitors should be flat molecules (Figure
1(a)) with specific dimensions depending on the isoform
(11.5 5.5 1.8 Å for hMAO-A and 8.5 5.1 1.8 Å for hMAO-B).
The pharmacophore reported in Figure 1(a) was inspired by
isatin and indole analogues which possess different enzyme spe-
cificities, inhibiting hMAO-B and hMAO-A, respectively14,15.
Although the dimensions of compounds may explain the different
affinities for the MAO isoforms (hMAO-A can accommodate larger
molecules than hMAO-B), the differences of the electron density
in the molecules play an important role in enzyme selectivity. As a
matter of the fact, follow-up studies focussed on the isosteric sub-
stitution of the nitrogen of the indole system with an oxygen
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atom or methylene group, to obtain respectively aurone16 and
indanone derivatives17,18 (Figure 1(b)).
Aurone derivatives (Figure 1(b,I)) showed selective inhibition
towards rat MAO-B (rMAO-B) with IC50 values ranging from 11.6 to
26.3mM, without activity against the A isoform. On the other
hand, indanone derivatives (Figure 1(b,II)) showed good inhibitory
profile in the low micromolar range especially for hMAO-B
(0.0052< IC50 hMAO-B (mM) <2.74). All these structures (indole
analogues, aurone, and indanone derivatives) share a common
structural feature, and is thus similar to the chalcone moiety
(highlighted in red), whose ability to bind to hMAO enzymes have
been reported in the past by our group19. With the aim to explore
new structures for the inhibition of hMAO, we proposed a new
scaffold based on benzo[b]thiophen-3-ol structure (Figure 1(c)).
This scaffold retained some similarity with the compounds dis-
cussed above, for example the presence of bicyclic system con-
nected with a “bridge” to an aromatic/heteroaromatic ring.
Other important differences among these scaffolds are the isos-
teric replacement of the oxygen atom of aurones with sulphur
and the presence of 1,3-diketonic system that, via keto-enol tauto-
merism, generates the corresponding chalcone while also possess-
ing the potential for metal chelation20. This is a very interesting
aspect and provides the possibility to obtain multi-target-directed
drugs in the light of the evidence that some cations may contrib-
ute to neurodegeneration in CNS tissues. As mentioned above,
these ions are implicated in the Fenton reaction6 which catalyses
the production of hydroxyl radicals from hydrogen peroxide, a
well-known by-product of MAO enzymatic activity21,22. Since
hydroxyl radicals possess a very short half-life, estimated at 1 ns,
they can be highly toxic to biomolecules and the use of chelating
agents should repair this metal dyshomeostasis leading to
reduced damage derived from oxidative stress.
The structure of benzo[b]thiophen-3-ol has been previously
studied from a chemical point of view and several research
groups have proposed synthetic strategies to obtain this class of
compounds23–25. Here, we propose a new one-step, very simple
synthetic procedure which allowed us to obtain the desired com-
pounds PM1-PM20 (Scheme 1). Methyl 2-mercaptobenzoate and
a-bromo acetophenone in equimolar amount, were reacted in
methanol in the presence of potassium hydroxide. The reaction
was performed in a nitrogen atmosphere (to avoid sulphur oxida-
tion) and at room temperature for 1–2 h. After this time, an
excess of potassium hydroxide was added, and the temperature
was raised to 60 C. The completion of reactions was usually
reached in 4–5 h producing all the compounds PM1-PM20 in
high yields.
We proposed a reaction mechanism for the synthesis of the ben-
zo[b]thiophen-3-ol derivatives as reported in Scheme 2. The first
phase of the reaction is the nucleophilic attack of the deprotonated
thiol group on a-position of the ketone to obtain the intermediate
W. After an intramolecular crossed aldolic reaction between the
methylene y and methyl ester functional group with consequent
methanol elimination, the benzo[b]thiophen-3-ol is obtained26.
The synthesised compounds PM1-PM20 were then evaluated
as hMAO inhibitors using the recombinant hMAOs as enzyme
sources. The inhibitory activities of compounds PM1-PM20 are
(a)
(b)
(c)
Figure 1. (a) Molecular properties of the pharmacophore for the inhibition of the hMAOs. The part of the structure shown in red corresponds to the chalcone moiety
(adapted from reference13); (b) Structure of aurone (I) and indanone (II) derivatives; (c) Benzo[b]thiophen-3-ol scaffold: similarities and differences with previously
reported compounds.
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summarised in Table 1 along with selectivity index (SI) values
given as the ratio (IC50 hMAO-A)/(IC50 hMAO-B).
Compounds that showed the best IC50 values towards hMAO-B
(PM4, PM5, PM6, PM9, PM10, PM12, and PM13) were also tested
in cortex synaptosomes in both basal and LPS-induced inflamma-
tory conditions, to estimate the capability of reducing 3,4-dihy-
droxyphenylacetic acid/ dopamine (DOPAC/DA) ratio and lactate
dehydrogenase (LDH) activity27–29. The most active compounds
(PM4, PM5, PM6, PM9, PM10, PM12, and PM13) were further
tested for their antioxidant and metal chelating activity with the
aim to demonstrate the possibility of ancillary effects in neurode-
generative disorders. Finally, all the compounds were analysed by
molecular modelling to better corroborate the biological data and
to further determine which tautomer was responsible for the
observed biological activity.
2. Experimental protocols
2.1. General
Unless otherwise indicated, all reactions were carried out under
a positive nitrogen pressure (balloon pressure) in washed and
oven-dried glassware. Solvents and reagents were used as sup-
plied without further purification. All melting points were meas-
ured on a StuartVR melting point apparatus SMP1 and are
uncorrected (temperatures are reported in C). Fluorescence spec-
trophotometry was carried out with a Varian Cary Eclipse fluores-
cence spectrophotometer. 1H and 13C NMR spectra were recorded
at 400 and 101MHz, respectively, on a Bruker spectrometer using
CDCl3 and DMSO-d6 as the solvents at room temperature. The
samples were analysed with a final concentration of 30mg/ml.
Chemical shifts are expressed as d units (parts per million) relative
to the solvent signal. 1H spectra are reported as follows: dH (spec-
trometer frequency, solvent): chemical shift/ppm (multiplicity,
J-coupling constant(s), number of protons, assignment). 13C spec-
tra are reported as follows: dC (spectrometer frequency, solvent):
chemical shift/ppm (J-coupling constant C-F, assignment).
Multiplicity is abbreviated as follows: br – broad; s – singlet; d –
doublet; t – triplet; q – quartette; and m – multiplet. Coupling
constants J are given in Hertz (Hz). The processing and analyses of
the NMR data were carried out with MestreNova. Column chroma-
tography was carried out using Sigma-AldrichVR (St. Louis, MO), sil-
ica gel (high purity grade, pore size 60 Å, 230–400 mesh particle
size). All the purifications and reactions were monitored by TLC
Scheme 1. Synthesis of compounds PM1-PM20.
Scheme 2. Proposed mechanism of reaction.
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which was performed on 0.2mm thick silica gel-aluminium backed
plates (60 F254, Merck, Kenilworth, NJ)Visualisation was carried out
under ultra-violet irradiation (254 nm). Elemental analyses for C, H,
and N were recorded on a Perkin-Elmer 240 B microanalyzer
obtaining analytical results within ± 0.4% of the theoretical values
for all compounds. Where given, systematic compound names are
those generated by ChemBioDraw Ultra 12.0 following IUPAC con-
ventions. Microsomes from insect cells containing recombinant
hMAO-A and hMAO-B (5mg protein/ml) and kynuramine dihydro-
bromide were obtained from Sigma-Aldrich (St. Louis, MO).
2.2. Chemistry
In an oven dried flask containing a stirring solution of methyl 2-
mercaptobenzoate (1.0 equiv.) in methanol (10ml), freshly ground
potassium hydroxide (1.5 equiv.) and the appropriate a-bromoace-
tophenone (1.0 equiv.) were added. The reaction was performed
at room temperature for 1–2 h. After this time, an excess of potas-
sium hydroxide was added (1.5 equiv.) and the temperature was
raised to 60 C. The progression of reaction was monitored by TLC
and completion was usually reached in 4–5 h. The reaction was
poured into ice-cold water (30ml) and the pH was adjusted to the
value of 7 with a 2N HCl solution to induce the complete pre-
cipitation of the desired compound. The resulting benzo[b]thio-
phen-3-ol was collected by vacuum filtration and washed with hot
methanol (20ml). This procedure was used in order to obtain all
the compounds PM1-PM20 in high yields and a good level
of purity.
2.2.1. (3-Hydroxybenzo[b]thiophen-2-yl)(phenyl)methanone (PM1)
Yellow powder, mp 118–120 C, 80% yield; 1H NMR (400MHz,
DMSO-d6): d 7.48–7.52 (m, 1H, benzothiophene), 7.58–7.72 (m, 3H
Ar þ 1H benzothiophene), 7.92–7.95 (m, 2H, Ar), 7.98 (d, J¼ 8.2 Hz,
1H, benzothiophene), 8.05 (d, J¼ 8.0 Hz, 1H, benzothiophene),
12.02 (brs, 1H, OH, D2O exch.).
13C NMR (101MHz, DMSO-d6): d
112.2 (benzothiophene), 123.9 (benzothiophene), 124.0 (benzo-
thiophene), 125.5 (benzothiophene), 128.8 (Ar), 129.1 (Ar), 130.4
(benzothiophene), 131.1 (Ar), 133.1 (Ar), 138.6 (benzothiophene),
140.0 (benzothiophene), 160.3 (Cbenzothiophene-OH), 190.9 (C═ O).
Anal. Calcd for C15H10O2S: C, 70.80; H, 3.96. Found: C, 70.85;
H, 3.99.
2.2.2. (3-Hydroxybenzo[b]thiophen-2-yl)(o-tolyl)methanone (PM2)
Yellow powder, mp 131–133 C, 86% yield; 1H NMR (400MHz,
CDCl3): d 2.50 (s, 3H, CH3), 7.32–7.36 (m, 2H, Ar), 7.43–7.48 (m, 1H
Ar þ 1H benzothiophene), 7.54–7.58 (m, 1H, benzothiophene),
7.63–7.65 (m, 1H, Ar), 7.71 (d, J¼ 8.2 Hz, 1H, benzothiophene), 8.09
(d, J¼ 8.0 Hz, 1H, benzothiophene), 12.84 (brs, 1H, OH, D2O exch.).
13C NMR (101MHz, CDCl3): d 19.7 (CH3), 112.0 (benzothiophene),
123.1 (benzothiophene), 124.0 (benzothiophene), 124.7 (benzo-
thiophene), 125.5 (Ar), 127.4 (Ar), 130.0 (benzothiophene), 130.5
(benzothiophene), 130.9 (Ar), 131.3 (Ar), 136.3 (Ar), 138.3 (Ar),
141.0 (benzothiophene), 160.3 (Cbenzothiophene -OH), 190.9 (C═O).
Anal. Calcd for C16H12O2S: C, 71.62; H, 4.51. Found: C, 71.68;
H, 4.52.
2.2.3. (3-Hydroxybenzo[b]thiophen-2-yl)(m-tolyl)methanone (PM3)
Yellow powder, mp 122–124 C, 76% yield; 1H NMR (400MHz,
CDCl3): d 2.49 (s, 3H, CH3), 7.44–7.48 (m, 2H Ar þ 1H benzothio-
phene), 7.56–7.60 (m, 1H, benzothiophene), 7.76 (d, J¼ 8.2 Hz, 1H,
benzothiophene), 7.87–7.89 (m, 2H, Ar), 8.09 (d, J¼ 8.0 Hz, 1H, ben-
zothiophene), 13.49 (brs, 1H, OH, D2O exch.).
13C NMR (101MHz,
CDCl3): d 21.5 (CH3), 109.7 (benzothiophene), 123.0 (benzothio-
phene), 124.0 (benzothiophene), 124.7 (benzothiophene), 125.6
(Ar), 128.6 (Ar), 128.9 (Ar), 130.1 (benzothiophene), 130.3 (benzo-
thiophene), 133.4 (Ar), 138.3 (Ar), 138.7 (Ar), 140.8 (benzothio-
phene), 165.3 (Cbenzothiophene-OH), 192.1 (C═ O). Anal. Calcd for
C16H12O2S: C, 71.62; H, 4.51. Found: C, 71.64; H, 4.50.
2.2.4. (3-Hydroxybenzo[b]thiophen-2-yl)(p-tolyl)methanone (PM4)
Yellow powder, mp 99–101 C, 77% yield; 1H NMR (400MHz,
CDCl3): d 2.49 (s, 3H, CH3), 7.35–7.37 (m, 2H, Ar), 7.43–7.47 (m, 1H,
benzothiophene), 7.55–7.59 (m, 1H, benzothiophene), 7.75 (d,
J¼ 8.2 Hz, 1H, benzothiophene), 7.99–8.01 (m, 2H, Ar), 8.09 (d,
J¼ 8.0 Hz, 1H, benzothiophene), 13.6 (brs, 1H, OH, D2O exch.). 13C
NMR (101MHz, CDCl3): d 21.7 (CH3), 109.5 (benzothiophene), 122.9
(benzothiophene), 123.9 (benzothiophene), 124.7 (benzothio-
phene), 128.6 (Ar), 129.4 (Ar), 130.0 (benzothiophene), 130.3 (ben-
zothiophene), 135.5 (Ar), 140.7 (benzothiophene), 143.5 (Ar), 165.3
(Cbenzothiophene-OH), 191.4 (C═ O). Anal. Calcd for C16H12O2S: C,
71.62; H, 4.51. Found: C, 71.59; H, 4.47.
2.2.5. (3-Hydroxybenzo[b]thiophen-2-yl)(3-methoxyphenyl)me-
thanone (PM5)
Yellow powder, mp 77–79 C, 83% yield; 1H NMR (400MHz, CDCl3):
d 3.93 (s, 3H, OCH3), 7.16–7.19 (m, 1H, Ar), 7.44–7.49 (m, 1H Ar þ
1H benzothiophene), 7.56–7.60 (m, 1H Ar þ 1H benzothiophene),
7.66–7.69 (m, 1H, Ar), 7.76 (d, J¼ 8.2 Hz, 1H, benzothiophene),
7.87–7.89 (m, 2H, Ar), 8.09 (d, J¼ 8.1 Hz, 1H, benzothiophene),
13.45 (brs, 1H, OH, D2O exch.).
13C NMR (101MHz, CDCl3): d 55.5
(OCH3), 109.7 (benzothiophene), 119.2 (Ar), 120.8 (Ar), 123.0 (ben-
zothiophene), 124.0 (benzothiophene), 124.8 (benzothiophene),
129.8 (Ar), 130.2 (benzothiophene), 130.3 (benzothiophene), 139.5
(Ar), 140.8 (benzothiophene), 159.8 (Ar), 165.4 (Cbenzothiophene-OH),
191.6 (C═O). Anal. Calcd for C16H12O3S: C, 67.59; H, 4.25. Found: C,
67.61; H, 4.29.
2.2.6. (3-Hydroxybenzo[b]thiophen-2-yl)(4-methoxyphenyl)metha-
none (PM6)
Yellow powder, mp 181–183 C, 73% yield; 1H NMR (400MHz,
DMSO-d6): d 3.88 (s, 3H, OCH3), 7.13–7.15 (m, 2H, Ar), 7.49–7.53
(m, 1H, benzothiophene), 7.62–7.66 (m, 1H, benzothiophene),
7.98–8.01 (m, 2H Ar þ 1H benzothiophene), 8.03 (d, J¼ 8.0 Hz, 1H,
benzothiophene), 12.76 (brs, 1H, OH, D2O exch.).
13C NMR
(101MHz, DMSO-d6): d 56.1 (OCH3), 111.4 (benzothiophene), 114.6
(Ar), 123.7 (benzothiophene), 123.9 (benzothiophene), 125.5 (ben-
zothiophene), 130.3 (benzothiophene), 130.7 (benzothiophene),
130.9 (Ar), 131.3 (Ar), 139.7 (benzothiophene), 160.9 (Ar), 163.5
(Cbenzothiophene-OH), 189.5 (C═ O). Anal. Calcd for C16H12O3S: C,
67.59; H, 4.25. Found: C, 67.63; H, 4.24.
2.2.7. (3-Fluorophenyl)(3-hydroxybenzo[b]thiophen-2-yl)methanone
(PM7)
Yellow powder, mp 133–135 C, 82% yield; 1H NMR (400MHz,
CDCl3): d 7.31–7.36 (m, 1H, Ar), 7.45–7.49 (m, 1H, benzothiophene),
7.52–7.62 (m, 1H Ar þ 1H benzothiophene), 7.74–7.77 (m, 1H Ar þ
1H benzothiophene), 7.88 (d, J¼ 7.7 Hz, 1H, Ar), 8.09 (d, J¼ 8.1 Hz,
1H, benzothiophene), 13.49 (brs, 1H, OH, D2O exch.).
13C NMR
(101MHz, CDCl3): d 109.4 (benzothiophene), 115.4 (d, JC-F¼
23.1 Hz, Ar), 119.5 (d, JC-F ¼ 21.3 Hz, Ar), 123.0 (benzothiophene),
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124.1 (benzothiophene), 124.2 (d, JC-F ¼ 3.2 Hz, Ar), 124.9 (benzo-
thiophene), 130.2 (benzothiophene), 130.4 (benzothiophene),
130.4 (d, JC-F¼7.8 Hz, Ar), 140.2 (d, JC-F¼6.8 Hz, Ar), 140.8 (benzo-
thiophene), 162.7 (d, JC-F¼248.5 Hz, Ar), 165.8 (Cbenzothiophene-OH),
190.2 (C═O). Anal. Calcd for C15H9FO2S: C, 66.17; H, 3.33. Found: C,
66.18; H, 3.37.
2.2.8. (4-Fluorophenyl)(3-hydroxybenzo[b]thiophen-2-yl)methanone
(PM8)
Yellow powder, mp 127–129 C, 87% yield; 1H NMR (400MHz,
CDCl3): d 7.12 (t, J¼ 8.6 Hz, 2H, Ar), 7.34 (t, J¼ 7.6 Hz, 1H, benzo-
thiophene), 7.46 (t, J¼ 7.6 Hz, 1H, benzothiophene), 7.63 (d,
J¼ 8.2 Hz, 1H, benzothiophene), 7.95–8.01 (m, 2H Ar þ 1H benzo-
thiophene), 13.32 (brs, 1H, OH, D2O exch.).
13C NMR (101MHz,
CDCl3): d 109.2 (benzothiophene), 115.9 (d, JC-F¼21.9 Hz, Ar), 123.0
(benzothiophene), 124.0 (benzothiophene), 124.8 (benzothio-
phene), 130.2 (benzothiophene), 130.3 (benzothiophene), 131.0 (d,
JC-F ¼ 9.2 Hz, Ar), 134.4 (d, JC-F¼3.0 Hz, Ar), 140.6 (benzothio-
phene), 165.4 (d, JC-F¼254.7 Hz, Ar), 165.6 (Cbenzothiophene-OH),
190.2 (C═O). Anal. Calcd for C15H9FO2S: C, 66.17; H, 3.33. Found: C,
66.20; H, 3.39.
2.2.9. (3-Chlorophenyl)(3-hydroxybenzo[b]thiophen-2-yl)methanone
(PM9)
Yellow powder, mp 166–168 C, 89% yield; 1H NMR (400MHz,
CDCl3): d 7.45–7.52 (m, 1H Ar þ 1H benzothiophene), 7.58–7.62
(m, 1H Ar þ 1H benzothiophene), 7.76 (d, J¼ 8.2 Hz, 1H, benzo-
thiophene), 7.94–7.96 (m, 1H, Ar), 8.03–8.04 (m, 1H, Ar), 8.09 (d,
J¼ 8.0 Hz, 1H, benzothiophene), 13.29 (brs, 1H, OH, D2O exch.).
13C NMR (101MHz, CDCl3): d 109.4 (benzothiophene), 123.0 (ben-
zothiophene), 124.1 (benzothiophene), 124.9 (benzothiophene),
126.5 (Ar), 128.5 (Ar), 130.0 (Ar), 130.2 (benzothiophene), 130.5
(benzothiophene), 132.6 (Ar), 135.0 (Ar), 139.8 (Ar), 140.8 (benzo-
thiophene), 165.7 (Cbenzothiophene-OH), 190.2 (C═O). Anal. Calcd for
C15H9ClO2S: C, 62.40; H, 3.14. Found: C, 62.42; H, 3.11.
2.2.10. (4-Chlorophenyl)(3-hydroxybenzo[b]thiophen-2-yl)metha-
none (PM10)
Yellow powder, mp 164–166 C, 88% yield; 1H NMR (400MHz,
CDCl3): d 7.44–7.48 (m, 1H, benzothiophene), 7.52–7.55 (m, 2H,
Ar), 7.57–7.61 (m, 1H, benzothiophene), 7.75 (d, J¼ 8.2 Hz, 1H, ben-
zothiophene), 8.00–8.04 (m, 2H, Ar), 8.08 (d, J¼ 8.1 Hz, 1H, benzo-
thiophene), 13.40 (brs, 1H, OH, D2O exch.).
13C NMR (101MHz,
CDCl3): d 109.3 (benzothiophene), 123.0 (benzothiophene), 124.1
(benzothiophene), 124.9 (benzothiophene), 129.1 (Ar), 129.9 (Ar),
130.2 (benzothiophene), 130.4 (benzothiophene), 136.5 (Ar), 139.1
(Ar), 140.7 (benzothiophene), 165.7 (Cbenzothiophene-OH), 190.3 (C═
O). Anal. Calcd for C15H9ClO2S: C, 62.40; H, 3.14. Found: C, 62.35;
H, 3.17.
2.2.11. (2,4-Dichlorophenyl)(3-hydroxybenzo[b]thiophen-2-yl)me-
thanone (PM11)
White powder, mp 149–151 C, 88% yield; 1H NMR (400MHz,
DMSO-d6): d 7.44 (t, J¼ 7.6 Hz, 1H, benzothiophene), 7.58–7.60 (m,
2H Ar þ 1H benzothiophene), 7.78 (s, 1H, Ar), 7.94 (d, J¼ 8.1 Hz,
1H, benzothiophene), 8.06 (d, J¼ 8.1 Hz, 1H, benzothiophene),
11.74 (brs, 1H, OH, D2O exch.).
13C NMR (101MHz, DMSO-d6): d
116.5 (benzothiophene), 124.2 (benzothiophene), 125.2 (benzo-
thiophene), 128.0 (Ar), 129.4 (Ar), 130.0 (Ar), 130.1
(benzothiophene), 131.2 (Ar), 132.2 (benzothiophene), 135.1 (Ar),
139.5 (benzothiophene), 140.0 (benzothiophene), 157.3
(Cbenzothiophene-OH), 186.7 (C═O). Anal. Calcd for C15H8Cl2O2S: C,
55.75; H, 2.50. Found: C, 55.80; H, 2.53.
2.2.12. (3-Bromophenyl)(3-hydroxybenzo[b]thiophen-2-yl)metha-
none (PM12)
Yellow powder, mp 169–171 C, 90% yield; 1H NMR (400MHz,
CDCl3): d 7.42–7.49 (m, 1H Ar þ 1H benzothiophene), 7.58–7.62
(m, 1H, benzothiophene), 7.74–7.77 (m, 1H Ar þ 1H benzothio-
phene), 7.99 (d, J¼ 7.8 Hz, 1H, Ar), 8.09 (d, J¼ 8.0 Hz, 1H, benzo-
thiophene), 8.18–8.19 (m, 1H, Ar), 13.27 (brs, 1H, OH, D2O exch.).
13C NMR (101MHz, CDCl3): d 109.4 (benzothiophene), 123.0 (Ar),
123.1 (benzothiophene), 124.1 (benzothiophene), 124.9 (benzo-
thiophene), 126.9 (Ar), 130.1 (benzothiophene), 130.3 (Ar), 130.5
(benzothiophene), 131.4 (Ar), 135.5 (Ar), 140.0 (Ar), 140.8 (benzo-
thiophene), 165.7 (Cbenzothiophene-OH), 190.1 (C═O). Anal. Calcd for
C15H9BrO2S: C, 54.07; H, 2.72. Found: C, 54.10; H, 2.76.
2.2.13. (4-Bromophenyl)(3-hydroxybenzo[b]thiophen-2-yl)methanone
(PM13)
Yellow powder, mp 168–170 C, 84% yield; 1H NMR (400MHz,
CDCl3): d 7.46 (t, J¼ 7.6 Hz, 1H, benzothiophene), 7.59 (t, J¼ 7.6 Hz,
1H, benzothiophene), 7.70 (d, J¼ 8.5 Hz, 2H, Ar), 7.75 (d, J¼ 8.2 Hz,
1H, benzothiophene), 7.94 (d, J¼ 8.5 Hz, 2H, Ar), 8.08 (d, J¼ 8.0 Hz,
1H, benzothiophene), 13.39 (brs, 1H, OH, D2O exch.).
13C NMR
(101MHz, CDCl3): d 109.3 (benzothiophene), 123.0 (benzothio-
phene), 124.1 (benzothiophene), 124.9 (benzothiophene), 127.7
(Ar), 130.0 Ar), 130.2 (benzothiophene), 130.4 (benzothiophene),
132.0 (Ar), 136.9 (Ar), 140.7 (benzothiophene), 165.7
(Cbenzothiophene-OH), 190.4 (C═ O). Anal. Calcd for C15H9BrO2S: C,
54.07; H, 2.72. Found: C, 54.08; H, 2.72.
2.2.14. 4–(3-Hydroxybenzo[b]thiophene-2-carbonyl)benzonitrile
(PM14)
Orange powder, mp 176–178 C, 81% yield; 1H NMR (400MHz,
DMSO-d6): d 7.48 (t, J¼ 7.6 Hz, 1H, benzothiophene), 7.62 (t,
J¼ 7.6 Hz, 1H, benzothiophene), 7.96–8.04 (m, 4H Ar þ 1H benzo-
thiophene), 8.08 (d, J¼ 8.1 Hz, 1H, benzothiophene), 11.95 (brs, 1H,
OH, D2O exch.).
13C NMR (101MHz, DMSO-d6): d 114.2 (Ar), 114.5
(benzothiophene), 118.8 (CN), 124.1 (benzothiophene), 124.2 (ben-
zothiophene), 125.4 (benzothiophene), 129.4 (Ar), 130.2 (benzo-
thiophene), 131.8 (benzothiophene), 132.8 (Ar), 140.0
(benzothiophene), 143.1 (Ar), 158.3 (Cbenzothiophene-OH), 188.9 (C═
O). Anal. Calcd for C16H9NO2S: C, 68.80; H, 3.25; N, 5.01. Found: C,
68.83; H, 3.29; N, 4.97.
2.2.15. (3-Hydroxybenzo[b]thiophen-2-yl)(4-nitrophenyl)methanone
(PM15)
Orange powder, mp 205–207 C, 79% yield; 1H NMR (400MHz,
DMSO-d6): d 7.49 (t, J¼ 7.6 Hz, 1H, benzothiophene), 7.58–7.71 (m,
1H, benzothiophene), 7.99 (d, J¼ 8.1 Hz, 1H, benzothiophene),
8.06–8.11 (m, 2H Ar þ 1H benzothiophene), 8.38 (d, J¼ 8.1 Hz, 2H,
Ar), 11.94 (brs, 1H, OH, D2O exch.).
13C NMR (101MHz, DMSO-d6):
d 114.5 (benzothiophene), 123.9 (Ar), 124.1(benzothiophene),
124.2 (benzothiophene), 125.4 (benzothiophene), 130.1 (Ar), 130.2
(benzothiophene), 131.9 (benzothiophene), 140.0 (benzothio-
phene), 144.8 (Ar), 149.6 (Ar-NO2), 158.1 (Cbenzothiophene-OH), 188.5
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Table 1. Inhibitory activity (IC50) and selectivity index (SI) of compounds PM1-PM20 towards hMAO-A and
hMAO-B.
 
IC50 ± SD (µM)a 
SIb 
Compound Substituent hMAO-A hMAO-B 
PM1 
 
13.3 ± 0.29 7.39 ± 0.15 1.8 
PM2 
 
18.7 ± 2.99 23.4 ± 3.03 0.8 
PM3 
 
12.6 ± 1.58 1.81 ± 0.13 6.9 
PM4 
 
2.71 ± 0.14 0.47 ± 0.02 5.8 
PM5 
 
33.0 ± 0.88 0.78 ± 0.07 42.3 
PM6 
 
4.18 ± 0.77 0.28 ± 0.03 14.9 
PM7 
 
25.1 ± 2.17 1.44 ± 0.40 17.4 
PM8 
 
13.4 ± 0.92 2.28 ± 0.18 5.8 
PM9 51.0 ± 1.72 0.55 ± 0.09 92.7 
PM10 
 
13.8 ± 0.51 0.89 ± 0.07 15.5 
PM11 
 
43.4 ± 2.81 37.3 ± 1.01 1.2 
PM12 
 
63.2 ± 3.48 0.35 ± 0.08 180 
PM13 
 
21.1 ± 1.98 0.88 ± 0.08 23.9 
PM14 
 
21.2 ± 3.27 4.51 ± 0.13 4.7 
PM15 
 
18.8 ± 1.53 2.75 ± 0.02 6.8 
PM16 
 
50.1 ± 2.56 49.7 ± 1.90 1.0 
PM17 
 
53.8 ± 2.90 56.9 ± 5.62 0.9 
PM18 
 
6.44 ± 0.68 7.56 ± 0.70 0.8 
PM19 
 
36.5 ± 1.07 5.59 ± 0.74 6.5 
PM20 
 
42.5 ± 1.88 1.08 ± 0.097 39.4 
aValues are the mean ± SD of triplicate determinations. bSelectivity index for the MAO-B isoform, given as the
ratio: (IC50 hMAO-A)/(IC50 hMAO-B).
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(C═O). Anal. Calcd for C15H9NO4S: C, 60.20; H, 3.03; N, 4.68. Found:
C, 60.21; H, 3.05; N, 4.69.
2.2.16. (3-Hydroxybenzo[b]thiophen-2-yl)(pyridin-3-yl)methanone
(PM16)
Orange powder, mp 120–122 C, 79% yield; 1H NMR (400MHz,
DMSO-d6): d 7.47–7.51 (m, 1H, benzothiophene), 7.58–7.64 (m, 1H
Pyr þ 1H benzothiophene), 7.99 (d, J¼ 8.1 Hz, 1H, benzothio-
phene), 8.10 (d, J¼ 8.1 Hz, 1H, benzothiophene), 8.21–8.24 (m, 1H,
Pyr), 8.79–8.80 (m, 1H, Pyr), 9.00–9.01 (m, 1H, Pyr), 11.92 (brs, 1H,
OH, D2O exch.).
13C NMR (101MHz, DMSO-d6): d 109.5 (benzothio-
phene), 123.1 (benzothiophene), 123.8 (Pyr), 124.2 (benzothio-
phene), 125.1 (benzothiophene), 130.0 (benzothiophene), 130.7
(benzothiophene), 136.3 (Pyr), 136.4 (Pyr), 140.8 (benzothiophene),
148.8 (Pyr), 152.4 (Pyr), 165.9 (Cbenzothiophene-OH), 189.3 (C═ O).
Anal. Calcd for C14H9NO2S: C, 65.87; H, 3.55; N, 5.49. Found: C,
65.89; H, 3.57; N, 5.53.
2.2.17. (3-Hydroxybenzo[b]thiophen-2-yl)(pyridin-4-yl)methanone
(PM17)
Orange powder, mp 203–205 C, 85% yield; 1H NMR (400MHz,
CDCl3): d 7.46–7.50 (m, 1H, benzothiophene), 7.60–7.64 (m, 1H,
benzothiophene), 7.76 (d, J¼ 8.2 Hz, 1H, benzothiophene),
7.85–7.86 (m, 2H, Pyr), 8.10 (d, J¼ 8.1 Hz, 1H, benzothiophene),
8.87–8.89 (m, 2H, Pyr), 13.12 (brs, 1H, OH, D2O exch.).
13C NMR
(101MHz, CDCl3): d 109.4 (benzothiophene), 121.6 (Pyr), 123.1
(benzothiophene), 124.3 (benzothiophene), 125.1 (benzothio-
phene), 130.0 (benzothiophene), 130.9 (benzothiophene), 141.0
(benzothiophene), 144.7 (Pyr), 150.6 (Pyr), 165.4 (Cbenzothiophene-
OH), 189.7 (C═ O). Anal. Calcd for C14H9NO2S: C, 65.87; H, 3.55; N,
5.49. Found: C, 65.85; H, 3.50; N, 5.55.
2.2.18. (3-Hydroxybenzo[b]thiophen-2-yl)(thiophen-3-yl)methanone
(PM18)
Yellow powder, mp 182–184 C, 73% yield; 1H NMR (400MHz,
CDCl3): d 7.44–7.48 (m, 1H thiophene þ 1H benzothiophene),
7.57–7.61 (m, 1H, benzothiophene), 7.78 (d, J¼ 8.2 Hz, 1H, benzo-
thiophene), 7.80–7.81 (m, 1H, thiophene), 8.07 (d, J¼ 8.0 Hz, 1H,
benzothiophene), 8.39–8.40 (m, 1H, thiophene), 13.55 (brs, 1H, OH,
D2O exch.).
13C NMR (101MHz, CDCl3): d 109.4 (benzothiophene),
123.0 (benzothiophene), 123.9 (benzothiophene), 124.8 (benzo-
thiophene), 126.6 (thiophene), 127.6 (thiophene), 130.2 (benzo-
thiophene), 130.4 (benzothiophene), 132.2 (thiophene), 140.2
(thiophene), 141.0 (benzothiophene), 165.7 (Cbenzothiophene-OH),
184.6 (C═O). Anal. Calcd for C13H8O2S: C, 59.98; H, 3.10. Found: C,
60.02; H, 3.12.
2.2.19. [1,1’-biphenyl]-4-yl(3-hydroxybenzo[b]thiophen-2-yl)metha-
none (PM19)
Yellow powder, mp 162–164 C, 89% yield; 1H NMR (400MHz,
CDCl3): d 7.44–7.54 (m, 3H Ar þ 1H benzothiophene), 7.57–7.61
(m, 1H, benzothiophene), 7.69–7.71 (m, 2H, Ar), 7.77–7.80 (m, 2H
Ar þ 1H benzothiophene), 8.11 (d, J¼ 8.1 Hz, 1H, benzothiophene),
8.17–8.19 (m, 2H, Ar), 13.61 (brs, 1H, OH, D2O exch.).
13C NMR
(101MHz, CDCl3): d 109.6 (benzothiophene), 123.0 (benzothio-
phene), 124.0 (benzothiophene), 124.8 (benzothiophene), 127.3
(Ar), 127.4 (Ar), 128.3 (Ar), 129.0 (Ar), 129.1 (Ar), 130.2 (benzothio-
phene), 130.3 (benzothiophene), 136.9 (Ar), 139.8 (benzothio-
phene), 140.8 (Ar), 145.5 (Ar), 165.6 (Cbenzothiophene-OH), 191.14
(C═O) Anal. Calcd for C21H14O2S: C, 76.34; H, 4.27. Found: C,
76.38; H, 4.31.
2.2.20. (3-Hydroxybenzo[b]thiophen-2-yl)(naphthalen-2-yl)metha-
none (PM20)
Yellow powder, mp 126–128 C, 90% yield; 1H NMR (400MHz,
CDCl3): d 7.44–7.49 (m, 1H, benzothiophene), 7.57–7.68 (m, 2H Ar
þ 1H benzothiophene), 7.78 (d, 2H, J¼ 8.2 Hz, 1H, benzothio-
phene), 7.93–7.95 (m, 1H, Ar), 7.99–8.05 (m, 2H, Ar), 8.09–8.12 (m,
1H Ar þ 1H benzothiophene), 8.65 (s, 1H, Ar), 13.58 (brs, 1H, OH,
D2O exch.).
13C NMR (101MHz, CDCl3): d 109.8 (benzothiophene),
123.0 (benzothiophene), 124.0 (benzothiophene), 124.4 (Ar), 124.8
(benzothiophene), 127.0 (Ar), 127.9 (Ar), 128.5 (Ar), 128.7 (Ar),
129.5 (Ar), 129.9 (Ar), 130.2 (benzothiophene), 130.4 (benzothio-
phene), 132.4 (Ar), 135.3 (Ar), 135.3 (Ar), 139.8 (Ar), 140.8 (benzo-
thiophene), 145.5 (Ar), 165.6 (Cbenzothiophene-OH), 191.14 (C═ O).
Anal. Calcd for C19H12O2S: C, 74.98; H, 3.97. Found: C, 74.99;
H, 4.02.
2.3. Biological assays
2.3.1. hMAO-a and hMAO-B inhibition studies
IC50 values for the inhibition of hMAO-A and hMAO-B were meas-
ured according to the literature protocol30,31 with the commer-
cially available recombinant enzymes (Sigma-Aldrich, St. Louis,
MO) serving as enzyme sources. Kynuramine was used as sub-
strate for both hMAO isoforms. The oxidation of kynuramine by
the hMAOs yields 4-hydroxyquinoline which was measured by
fluorescence spectrophotometry. By assessing the hMAO activities
in the presence of a range of different inhibitor concentrations
(0.003–100 mM), the IC50 values were measured. The enzyme reac-
tions (200 ml) were carried out in white 96-well microtiter plates
(Eppendorf, Hamburg, Germany) in potassium phosphate buffer
(pH 7.4, 100mM) and contained kynuramine (50 mM), the test
inhibitors spanning at least three order of magnitude
(0.003–100 mM) and hMAO-A (0.0075mg protein/ml) or hMAO-B
(0.015mg protein/ml). The reactions were initiated with the add-
ition of enzyme, incubated for 20min at 37 C, and at endpoint
were treated with 2N NaOH (80ml) to terminate the enzyme reac-
tions. The fluorescence intensity of 4-hydroxyquinoline, the prod-
uct formed by the MAO-catalysed oxidation of kynuramine, was
measured (kex¼310 nm; kem¼400 nm). Sigmoidal plots of catalytic
rate versus logarithm of inhibitor concentration were constructed
and the IC50 values were estimated and reported as the mean-
± standard deviation (SD) of triplicate measurements.
2.3.2. Rat cortex synaptosomes
Male adult Sprague-Dawley rats (200–250 g) were housed in
Plexiglass cages (40 cm  25 cm  15 cm), two rats per cage, in
climatised colony rooms (22 ± 1 C; 60% humidity), on a 12 h/12 h
light/dark cycle (light phase: 07:00–19:00 h), with free access to
tap water and food, 24 h/d throughout the study, with no fasting
periods. Rats were fed a standard laboratory diet (3.5% fat, 63%
carbohydrate, 14% protein, 19.5% other components without cal-
oric value; 3.20 kcal/g). Housing conditions and experimentation
procedures were strictly in accordance with the European Union
ethical regulations on the care of animals for scientific research.
According to the recognised ethical principles of “Replacement,
Refinement and Reduction of Animals in Research”, specimens
were obtained as residual material from vehicle-treated rats rando-
mised in our previous experiments approved by Local Ethical
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Committee (University “G. d’Annunzio” of Chieti-Pescara) and
Italian Health Ministry (Project N. 880 definitely approved by
Italian Health Ministry on 24th August 2015).
Synaptosomes were prepared from a pool of frontal and par-
ietal cortex, which are more sensitive to oxidative stress compared
to other areas such as occipital and dorsal cortex32. Briefly, the
frontal and parietal cortex was quickly dissected, homogenised in
0.32M saccharose solution and centrifuged, first at 4000g for
10min, and then at 12000g for 20min, to isolate neuronal end-
ings from cell nuclei and glia. The purified synaptosomes were
suspended at 37 C, under O2/CO2 95%/5%, pH 7.35–7.45, in
Krebs-Ringer buffer (mM: NaCl 125, KCl 3, MgSO4 1.2, CaCl2 1.2,
Tris–HCl 10, glucose 10). Then, the synaptosome suspension was
divided into fractions (each containing 100mg of tissue in 3ml
medium) that were incubated at 37 C, under agitation for 30min
(incubation period), and treated with a pharmacological stimulus
as follows: i) Krebs-Ringer buffer (vehicle); ii) vehicle plus oxidant
stimulus [LPS 10lg/ml]; iii) vehicle plus oxidant stimulus and MAO
inhibitors (20 nM–1 lM). After the incubation period, synaptosome
suspension was centrifuged (12,000g for 20min) and the super-
natant assayed for LDH, DA, and DOPAC determination.
2.3.3. LDH activity determination
LDH activity was measured by evaluating the consumption of
NADH in 20mM HEPES-Kþ (pH 7.2), 0.05% bovine serum albumin,
20mM NADH and 2mM pyruvate using a microplate reader (exci-
tation 340 nm, emission 460 nm) according to manufacturer’s
protocol (Sigma-Aldrich, St. Louis, MO). Extracts were tested at
25mg/ml. Data were obtained from triplicate test and expressed
as relative variations compared to vehicle-treated cells33.
2.3.4. Neurotransmitter extraction and high-performance liquid
chromatography (HPLC) determination
Extracellular DA, 5-HT, and NE levels were analysed through HPLC
apparatus consisting of a Jasco (Tokyo, Japan) PU-2080 chromato-
graphic pump and an ESA (Chelmsford, MA) Coulochem III coulo-
metric detector, equipped with microdialysis cell (ESA-5014b)
porous graphite working electrode and solid-state palladium refer-
ence electrode. The analytical conditions for biogenic amine iden-
tification and quantification were selected as previously
reported34. Briefly, the analytical cell was set at 0.150 V, for
detector 1 and at þ0.300 V, for detector 2, with a range of 100 nA.
The chromatograms were monitored at the analytical detector 2.
Integration was performed by Jasco Borwin Chromatography soft-
ware version 1.5 . The chromatographic separation was performed
by isocratic elution on Phenomenex Kinetex reversed-phase col-
umn (C18, 150mm  4.6mm i.d., 2.6mm). The mobile phase was
(10:90, v/v) acetonitrile and 75mM, pH 3.00 phosphate buffer con-
taining octanesulfonic acid 1.8mM, EDTA 30mM and triethylamine
0.015% v:v. Flow rate was 0.6ml/min and the samples were manu-
ally injected through a 20ml loop. Neurotransmitter peaks were
identified by comparison with the retention time of pure standard.
Neurotransmitter concentrations in the samples were calculated
by linear regression curve (y¼bxþm) obtained with standard.
Neither internal nor external standard was necessary for neuro-
transmitter quantification and all tests performed for method val-
idation yielded results in accordance to limits indicated in official
guidelines for applicability in laboratory trials. The standard stock
solutions of DA and DOPAC at 2mg/ml were prepared in bi-dis-
tilled water containing 0.004% EDTA and 0.010% sodium bisul-
phite. The stock solutions were stored at 4 C. Work solutions
(1.25–20.00 ng/ml) were obtained daily progressively diluting stock
solutions in mobile phase.
2.3.5. Statistical analysis
GraphPad Prism version 5.01 for Windows (GraphPad Software,
San Diego, CA) was used as statistical analysis software.
Experiments were performed at least in triplicate and results are
presented as mean± standard deviation (SD). One-way analysis of
variance (ANOVA) followed by Newman–Keuls post-hoc test was
employed to assess significant differences (p<.05). As regards the
animals randomised for each experimental group, the number
was calculated on the basis of the “Resource Equation”
N¼(Eþ T)/T35.
2.4. Molecular modelling
All molecular modelling simulations were carried out by means of
the Schr€odinger Suite version 2018–1 (Schr€odinger LLC, NY)36.
Maestro GUI37 was employed to build the 3D theoretical struc-
tures of our derivatives. Both tautomers/conformers were taken
into account. Quantum mechanics optimisation was performed by
means of Jaguar38 software using the DFT B3LYP method and
6–311G as basis set. The resulting structure population was
estimated according to Boltzmann analysis at 300 K. Protein Data
Bank (PDB)39 crystallographic structures, deposited with the corre-
sponding codes 2Z5X40 and 6FW041, were used as receptor mod-
els of hMAO-A and hMAO-B, respectively. Both PDB structures
were prepared as follows before the docking simulation: missing
atoms and FAD bond order were fixed, hydrogen atoms were
added and co-crystallised water molecules and ligands, harmine
and chlorophenyl-chromone-carboxamide for 2Z5X and 6FW0,
respectively, were removed. After preparation, the Glide42 software
was used to generate ligand configurations in the enzymatic
clefts, which were defined by a regular box of about 64,000Å3
centred on the FAD N5 atom. Ligand structural flexibility was
taken into account by the software by a maximum of 10 docking
configurations for ligand were generated. The binding affinity was
estimated by means of the standard precision (SP) scoring func-
tion and the top-ranked complexes, according to Glide Score,
were considered for the binding modes analyses. In order to
evaluate the non-bonded interaction energy contribution, the
Glide Energy and its components Glide Ecoul and EvdW
were examined.
2.5. Radical scavenging and chelating activities
2.5.1. Free radical scavenging activity (DPPH)
Each test solution (1ml) was added to 2,2-diphenyl-1-picrylhydra-
zyl (DPPH) solution (4ml, 0.004% methanolic solution). The sample
absorbance was noted at 517 nm after 30min incubation at room
temperature in the dark43.
2.5.2. 2,2-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS)
radical cation scavenging activity
ABTS.þ radical cation was produced in situ by reacting a 7mM
ABTS solution with 2.45mM potassium persulfate and allowing
the mixture to incubate for 12–16 h in the dark at room tempera-
ture. The ABTS solution was first diluted with methanol to an
absorbance of 0.700 ± 0.02 at 734 nm. Each test solution (1ml) was
mixed with ABTS solution (2ml)44.
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2.5.3. Evaluation of total antioxidant capacity by phosphomolyb-
denum assay
Each test solution (0.3ml) was mixed with 3ml of reagent solution
(0.6M sulphuric acid, 28mM sodium phosphate and 4zmM
ammonium molybdate). The sample absorbance was read at
695 nm after 90min incubation at 95 C45.
2.5.4. Cupric ion reducing (CUPRAC) method
Each test solution (0.5ml) was added to reaction mixture contain-
ing CuCl2 (1ml, 10mM), neocuproine (1ml, 7.5mM) and NH4Ac
buffer (1ml, 1M, pH 7.0). Similarly, a blank was prepared as fol-
lows: sample solution (0.5ml) and reaction mixture (3ml) without
CuCl2. The absorbances were read at 450 nm after 30min of incu-
bation at room temperature46.
2.5.5. Ferric reducing antioxidant power (FRAP) method
Each sample solution (0.1ml) was added to the FRAP reagent
(2ml) containing acetate buffer (0.3M, pH 3.6), 2,4,6-tris(2-pyridyl)-
s-triazine (TPTZ) (10mM) in 40mM HCl and ferric chloride (20mM)
in a ratio of 10:1:1 (v/v/v). Then, the absorbance was read at
593 nm after a 30min incubation at room temperature47.
2.5.6. Metal chelating activity on ferrous ions
Each test solution (2ml) was added to FeCl2 solution (0.05ml,
2mM). The reaction was initiated by the addition of 5mM ferro-
zine (0.2ml). Similarly, a blank was prepared as follows: test solu-
tion (2ml), FeCl2 solution (0.05ml, 2mM) and water (0.2ml). The
absorbances of sample and blank were subsequently noted at
562 nm after 10min incubation at room temperature48.
3. Result and discussion
3.1. In vitro MAO inhibition study
The synthesised compounds PM1-PM20 were evaluated as poten-
tial inhibitors of hMAO-A and hMAO-B, and the activities are given
as the IC50 values in Table 1. Among these derivatives, only com-
pounds PM2, PM17, and PM18 were superior inhibitors of hMAO-
A compared to hMAO-B, although only to a small extent. All other
compounds were selective hMAO-B inhibitors with IC50 values in
the micromolar/low micromolar range. The simplest compound of
this series, PM1, containing an unsubstituted phenyl ring bound
to the carbonyl “bridge,” showed similar inhibition against both
the isoforms with poor selectivity (IC50 hMAO-A¼ 13.3 mM; IC50
hMAO-B¼ 7.39 mM; SI ¼ 1.8). When substitution on the phenyl
ring occurred, we observed different effects depending on the
position and chemical nature of the substituent. In fact, the pres-
ence of a weak electron donor such as the methyl group on phe-
nyl ring, improved inhibition activity towards hMAO-B if placed on
the meta (PM3, IC50 hMAO-B¼ 1.81 mM) or para (PM4, IC50 hMAO-
B¼ 0.47 mM) positions. PM4 also displayed improved inhibition
activity towards hMAO-A (PM4, IC50 hMAO-A¼ 2.71 mM), account-
ing for the slightly reduced SI compared with PM3 (PM3, IC50
hMAO-A¼ 12.6 mM). On the other hand, when this substituent was
located at the ortho-position, we observed reduced inhibition
activity against both the isoforms, with a slight preference for
hMAO-A (PM2, IC50 hMAO-A¼ 18.7 mM; IC50 hMAO-B¼ 23.4mM; SI
¼ 0.8). A similar trend was observed for compounds substituted
with the methoxy group, which is considered to be a stronger
electron donor than the methyl (PM5 and PM6). For these two
derivatives, we also recorded different inhibition activities towards
hMAO-B, with the best efficacy recorded when the methoxy group
was placed on the para-position of the phenyl ring (PM6, IC50
hMAO-B¼ 0.28mM). Similar to the methyl-substituted derivatives,
the placement of the methoxy substituent on the meta-position
negatively affected inhibition activity against hMAO-A (PM5, IC50
hMAO-A¼ 33.0mM), thus improving the selectivity index (SI ¼
42.3). In the light of the above, it may be concluded that electron
donor groups improve inhibitory activity towards hMAO-B when
they are substituted on the meta- and para-positions.
Furthermore, when these groups are placed on the meta-position,
they also led to an increase in selectivity due to the reduction of
hMAO-A inhibition. A different trend was observed for halogen-
substituted derivatives (PM7-PM13). The data show that when the
substituent changed from fluoro to chloro and finally to bromo,
there was an increment of inhibitory activity and selectivity
towards hMAO-B, according to the increased size and reduced
electronegativity of the halogen, with the best inhibition and
selectivity shown by compound PM12 (IC50 hMAO-B¼ 0.35 mM; SI
¼ 180). In the light of the above, we conclude that halogens,
which represent electron-withdrawing groups, positively affect
both inhibition activity and selectivity when they are placed on
the meta position (e.g. PM12, IC50 hMAO-B¼ 0.35mM vs. PM13,
IC50 hMAO-B¼ 0.88 mM). This trend differs from that observed with
the electron donor groups (e.g. methyl or methoxy). Other com-
pounds such as PM14 and PM15, which are substituted on the
para position with CN and NO2, exhibited hMAO-B inhibition in
the low micromolar range (PM14, IC50 hMAO-B¼ 4.51 mM; PM15,
IC50 hMAO-B¼ 2.75 mM) with little selectivity between the two iso-
forms (PM14 SI ¼ 4.7; PM15 SI ¼ 6.8). The presence of a hetero-
cyclic ring for compounds PM16-PM19 negatively affected the
inhibition of hMAO-B. Finally, substitution of the phenyl ring with
the bulky naphthyl, but not biphenyl, improved both activity and
selectivity towards hMAO-B (PM20, IC50 hMAO-B¼ 1.08mM; SI
¼ 39.4).
3.2. Evaluation of DOPAC/DA ratio and LDH activity
Figures 2–5 show that deprenyl, an irreversible and selective
MAO-B inhibitor, and the new MAO inhibitors PM4, PM5, PM6,
PM9, PM10, PM12, and PM13 were able to exert modulatory
effects on cortex synaptosome DA/DOPAC ratio and LDH activity,
in both basal and LPS-induced inflammatory conditions.
Particularly, in Figure 2, it is possible to observe that deprenyl
and PM9 stimulated DOPAC/DA ratio, while PM10, PM12, and
PM13 inhibited basal DOPAC/DA ratio. On the other hand, no sig-
nificant effect was exerted by PM4, PM5, and PM6. When the
synaptosomes were challenged with an inflammatory LPS stimulus
(Figure 3), we observed that deprenyl and all PM inhibitors were
able to reduce DOPAC/DA ratio. Additionally, the present mole-
cules were more effective than deprenyl, with the highest inhibi-
tory effects displayed by PM10, PM12, and PM13.
DOPAC/DA ratio has long been proposed as an index of MAO-
B activity27, while microdialysis studies demonstrated the ability of
LPS to increase monoamine degradation and extracellular DOPAC
levels, in mouse prefrontal cortex49. Additionally, we have recently
reported that the pro-oxidant stimulus induced by amyloid b-pep-
tide could reduce monoamine levels, in rat cortex synapto-
somes50,51. Despite the agreement between the data reported in
Figure 3 and the MAO-B inhibitory activity described in Table 1,
the contrasting results obtained in basal condition (Figure 2), fol-
lowing PMs treatment, suggested the possible onset of pro-
inflammatory/pro-oxidant effects, which could have overcome the
intrinsic MAO inhibitory activity of these molecules, thus leading
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to increased DA turnover in rat cortex synaptosomes. In order to
test this hypothesis, we performed a second set of experiments to
evaluate the effect of deprenyl and the PM inhibitors on cortex
synaptosome LDH activity, in both basal and LPS-induced inflam-
matory condition (Figures 4 and 5).
LDH has long been considered a valuable marker of tissue
damage28,29. Additionally, antioxidants are able to downregulate
their ex vivo activity52. In this study, we observed that, except for
compound PM13, most of the PM inhibitors upregulated basal
LDH activity (Figure 4). Conversely, when synaptosomes were per-
fused with Krebs-Ringer buffer added with LPS, deprenyl inhibited
LDH activity at the lowest concentration (20 nM), which is very
close to its MAO-B IC50 value (17 nM)
53, despite exerting a
stimulatory effect at the highest tested concentration (1 mM). We
cannot exclude that the highest tested deprenyl concentration
(1 mM) could be toxic for cortex synaptosomes. Similarly, the PM
inhibitors displayed a significant LDH inhibitory activity, which is
more evident around their respective IC50 values, which are
included in the range 0.1–1mM (Table 1). Unlike deprenyl, all the
PM molecules inhibited LDH activity in the concentration range
(0.1–1lM). Our findings of reduced LPS-induced LDH activity by
both deprenyl (20 nM) and PMs (0.1–1lM), in rat cortex synapto-
somes, are consistent with the reported antioxidant activity of
MAO inhibitors in vivo54,55. On the other hand, we should consider
that the contrasting finding of stimulation of LDH activity (Figure
4), induced by deprenyl and PM inhibitors in basal condition,
Figure 2. Effect of the PM series of inhibitors on DOPAC/DA ratio in rat cortex synaptosomes. ANOVA: p<.0001; post-hoc: p<.001 vs. vehicle group. All the com-
pounds and deprenyl were tested at the same concentrations: 20 nM, 0.1lM, and 1lM.
Figure 3. Effect of the PM series of inhibitors on DOPAC/DA ratio in rat cortex synaptosomes challenged with LPS. ANOVA: p<.0001; post-hoc: p<.05, p<.001 vs.
LPS group. All the compounds and deprenyl were tested at the same concentrations: 20 nM, 0.1lM and 1lM.
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could be related to the employed ex vivo experimental model.
Specifically, it is well known that antioxidants in the cell medium
could exert pro-oxidative effects, by generating hydrogen perox-
ide and thus activating adaptive responses of cells to mild oxida-
tive stress. In this context, it is rational to hypothesise that our
results of blunted LPS-induced DOPAC/DA ratio and LDH activity,
in cortex synaptosomes treated with both deprenyl and PMs,
could be related to both MAO-B inhibition activity and improved
neuron antioxidant defence system. Taken together, these findings
support further investigation of the inhibition efficacy of the PM
series in in vivo experimental models of neuroinflammation and
oxidative stress. Particularly, future studies should involve
inhibitors PM10, PM12, and PM13 which exerted the highest
inhibitory efficacy on both LPS-induced DOPAC/DA ratio and LDH
activity (Figures 3 and 5).
3.3. Antioxidant and chelating activity
The most active compounds, investigated in the previous ex vivo
tests, were also studied as putative antioxidants and metal chelat-
ing agents in six in vitro spectrophotometric assays (Table 2). In
general, they were less potent with respect to the reference com-
pounds (Trolox as antioxidant and EDTA as chelating agent). Only
Figure 4. Effect of the PM series of inhibitors on LDH activity in rat cortex synaptosomes. ANOVA: p<.0001; post-hoc: p<.05, p<.01, p<.001 vs. vehicle group.
All the compounds and deprenyl were tested at the same concentrations: 20 nM, 0.1lM, and 1lM.
Figure 5. Effect of the PM series of inhibitors on LDH activity in rat cortex synaptosomes challenged with LPS. ANOVA: p<.0001; post-hoc: p<.05, p<.01,p<.001 vs. LPS group. All the compounds and deprenyl were tested at the same concentrations: 20 nM, 0.1lM, and 1lM.
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in the phosphomolybdenum test, were PM4 and PM5 comparable
to the reference drug.
3.4. Molecular modelling studies
Before evaluating target recognition, the possibility that our com-
pounds could exist in different tautomeric and conformational
states have been taken into account. In particular, the keto-enol
tautomerism and formation of intramolecular hydrogen bonds
(HBs) were investigated. For each compound, four states (Figure
6) were optimised at quantum mechanics level and submitted to
the Boltzmann population analysis at 300 K (Table S1).
For all compounds, the A1 form described a population larger
than 95% disregarding the substitution pattern on the aryl ring.
Therefore, this form was submitted to molecular docking simula-
tions. Docking analysis was focussed on the binding modes which
showed the best theoretical affinity according to the Glide Score.
Even if all compounds recognised both hMAO isoforms, they dis-
played a better theoretical interaction energy towards the hMAO-
B, excluding PM11 (Table 3). By computing r2 between theoretical
interaction energies and experimental inhibition data, considered
a -log(IC50), a strong linear correlation was not found (r
2¼0.53)
but a qualitative accord only. This was not a surprise because IC50
does not depend on the ligand target interaction only solvation
effect, ligand–-ligand, and ligand–other solutes interaction, not
considered in docking simulation, contribute. Analysing the theor-
etical complexes in terms of interaction energy contribution, we
found that, in general, the van der Waals (vdW) component
strongly favoured hMAO-B binding compared to hMAO-A
(Table 3).
We ascribe the hMAO-B preference of PM12, as reported in
Figure 7, to the intermolecular HB with Tyr326 side chain, which is
replaced in hMAO-A by the Ile335. Instead, in the hMAO-A pocket,
the binding of PM12 is hampered by the presence of the Phe208
which is replaced by Ile199 in hMAO-B, and thus assumes a differ-
ent binding mode with the benzothiophene moiety involved in
p–p stacking with Tyr407. However, such geometry didn’t prevent
unfavourable steric contacts to hMAO-A residues, Asn181
and Gln215.
Regarding the binding modes of the other derivatives, by vis-
ual inspections it was observed that, considering the orientation
of the benzothiophene portion, they could assume different bind-
ing modes in the hMAO-B active site, thus maintaining (PM2,
PM4, PM6, PM7, PM8, PM11, PM13, and PM17) (Figures S1–S8)
or losing (PM1, PM3, PM5, PM9, PM10, PM14, PM15, PM16,
PM18, PM19, and PM20) (Figures S9–S19) the intra-molecular HB.
In particular, derivatives PM1, PM4, PM6, PM7, PM11, PM13, and
PM19 directed the benzothiophene moiety towards the FAD
cofactor forming p–p interactions with active site aromatic amino
acids. Among these, only PM13 does not establish productive
contacts with the target. In contrast, the benzothiophene moiety
of other compounds was directed towards the entry gorge, which
resulted in the positioning of their hydroxyl group close to the
side chain of Tyr326 (PM2, PM3, PM5, PM8, PM9, PM10, PM15,
PM16, PM17, PM18, and PM20) or to the Ile199 backbone
(PM20), thus establishing HB to the target. Thus, the docking
results suggested that both p–p interactions and HBs with Tyr326
could play a key role in hMAO-B binding by most of the com-
pounds. Regarding hMAO-A, an intra-molecular HB was present
only in the docking poses of compounds PM1, PM17, and PM19
Table 2. IC50 values in the antioxidant assays (mM).
Samples DPPH ABTS FRAP CUPRAC Chelating ability Phosphomolybdenum assay
PM4 1.13 ± 0.01 >5 3.04 ± 0.03 1.88 ± 0.08 2.63 ± 0.42 4.40 ± 0.07
PM5 1.20 ± 0.02 >5 3.27 ± 0.08 1.14 ± 0.04 1.74 ± 0.19 4.40 ± 0.70
PM6 1.13 ± 0.01 3.18 ± 0.40 3.11 ± 0.11 1.62 ± 0.10 1.89 ± 0.08 >5
PM9 1.31 ± 0.04 2.49 ± 0.30 >5 3.57 ± 0.11 1.97 ± 0.09 >5
PM10 1.10 ± 0.01 3.28 ± 0.44 3.50 ± 0.07 1.41 ± 0.12 2.35 ± 0.13 >5
PM12 1.11 ± 0.01 3.42 ± 0.66 3.95 ± 0.16 1.13 ± 0.06 1.55 ± 0.28 >5
PM13 1.11 ± 0.01 2.68 ± 0.75 2.74 ± 0.10 1.43 ± 0.11 4.71 ± 1.04 >5
Trolox 0.09 ± 0.01 0.15 ± 0.01 0.20 ± 0.01 0.38 ± 0.01 2.63 ± 0.42 2.17 ± 0.10
EDTA – – – – 0.05 ± 0.01 –
 
A1       A2 
B1        B2 
Figure 6. 2 D structures of the conformers/tautomers investigated by quantum-
mechanics approach for each compound reported in Table 1.
Table 3. Theoretical interaction energy and its van der Waals (vdW) and
Coulomb (Coul) components are reported (in kcal/mol) for each ligand-tar-
get complex.
Compounds
hMAO-A hMAO-B
Interaction Energy Interaction Energy
VdW Coul Total VdW Coul Total
PM1 26.91 0.81 27.72 39.51 0.51 39.00
PM2 30.73 0.24 30.97 37.60 0.79 38.39
PM3 15.49 5.59 21.08 45.05 0.47 45.52
PM4 15.12 4.88 20.00 40.88 0.02 40.87
PM5 33.95 1.00 34.94 44.92 0.69 45.61
PM6 36.02 1.23 37.25 43.11 0.27 42.84
PM7 31.50 1.77 33.27 42.08 0.72 41.36
PM8 16.59 2.93 19.51 35.20 1.44 36.64
PM9 16.87 5.11 21.97 46.49 0.80 47.28
PM10 18.41 3.10 21.50 43.35 0.22 43.57
PM11 33.83 1.49 35.32 33.39 0.40 33.79
PM12 19.74 3.46 23.20 47.43 0.86 48.29
PM13 36.96 2.20 39.16 44.01 0.27 44.28
PM14 20.86 2.78 23.63 41.96 4.55 46.51
PM15 37.63 2.86 40.49 43.49 1.47 44.96
PM16 35.75 1.91 37.66 42.30 0.84 43.14
PM17 27.60 3.00 30.60 36.93 1.22 38.15
PM18 38.05 0.61 38.66 41.52 1.08 42.59
PM19 11.88 0.54 12.42 24.22 0.48 24.70
PM20 26.78 0.69 27.47 37.34 1.16 38.50
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(Figures S20–S22). Although the docking complexes of PM1 and
PM17 were quite similar, PM19 presented an opposite binding
orientation. In this respect, PM19 fitted in the hMAO-A cleft orien-
tated with the biphenyl moiety towards the outside. In addition,
for such compounds conflicts with both tyrosine residues close to
the cofactor and with the Ala111 backbone were suggested.
Similar to PM1 and PM17, compound PM11 (Figure S23) bound
with the benzothiophene core towards the entry of the active
site, but the presence of the 2,4-dichlorine substituted phenyl ring
led to the loss of the intra-molecular HB and to steric conflict with
Tyr69. This type of unfavourable interactions was present in most
of the hMAO-A docking solutions. For example, compounds PM2,
PM7, PM16, and PM18 (Figures S24–S27) displayed similar bind-
ing modes, but PM16 and PM18 formed HB and p–p interactions
with Phe208, whereas for PM2 and PM7, which possessed bulkier
substituents, unfavourable contacts with Phe208 and Tyr407 were
recorded. These contacts penalised the recognition of derivatives
PM3 (Figure S28) and PM9 (Figure S29) mainly due to interaction
with Tyr407 and Asn181 residues. Thus, the presence of a methyl
group or chlorine atom on the meta-position of the phenyl ring
resulted in similar unfavourable interactions with hMAO-A. For
compounds PM4, PM5, PM10, and PM20 (Figures S30–S33) simi-
lar docking poses were predicted. Favourable p–p contacts and
very similar recognition of derivatives PM6, PM8, PM13, PM14,
and PM15 (Figures S34–S38) by hMAO-A were predicted, although
these compounds are differently substituted on the para-position
of the phenyl ring. Particularly, the poses of PM6, PM13, and
PM15 were almost identical as well as those of PM8 and PM14.
Conversely, for compounds PM4 and PM10, substituted on the
para-position of the phenyl ring with a methyl group and chlorine
atom, respectively, the hydroxyl group was directed towards the
cofactor. In conclusion, molecular modelling proposed that ben-
zo[b]thiophen-3-ol tautomer A1 is the most populated state for
each compound of our series. In qualitative agreement to the bio-
logical assays, all derivatives were able to recognise both hMAOs
but preferred hMAO-B in terms of interaction energy and product-
ive contacts. Such a preference seemed to be driven by the vdW
interaction energy. Finally, in a large part of the most stable
theoretical complexes, the intra-molecular HB was lost and
replaced, in hMAO-B only, by a favourable inter-molecular inter-
action to Tyr326.
4. Conclusions
This library of benzothiophen-3-ol derivatives was demonstrated
to be a very interesting scaffold to design high potency hMAO-B
inhibitors, with IC50 values in the low micromolar to nanomolar
range. Moreover, the introduction of specific substituents on the
phenyl resulted in highly selective inhibition of this isozyme.
These compounds were also characterised by an effective ex vivo
hMAO-B inhibition as well as by limited antioxidant and chelating
properties. Furthermore, the binding modes and energies of the
designed molecules were predicted in silico, thus corroborating
the potential of this scaffold for the treatment of neurodegenera-
tive disorders.
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